Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the efficacy and safety of camrelizumab in combination
with SOX and/or apatinib in the treatment of locally advanced gastric cancer or
gastroesophageal junction adenocarcinoma.The primary endpoint was pathologic complete
response (PCR).In addition, secondary efficacy endpoints include R0 resection rate, objective
response rate (ORR), and 1-year progression-free survival rate (PFSR) . They were set to
demonstrate the therapeutic benefit of camrelizumab combined with SOX in patients 。
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University